After-Hours Movers 12/12: (SRPT) (IHRT) (ADBE) Higher; (UTI) (ASPU) (ORCL) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall St set for subdued open on final trading day of strong quarter
- Strong dollar pushes yen to 40-year low as traders test Japanese authorities
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Logitech dips as BofA downgrades stock on demand outlook concerns
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Adobe (ADBE) PT Raised to $334 at Griffin Securities
December 13, 2019 7:59 AM ESTGriffin Securities analyst Jay Vleeschhouwer raised the price target on Adobe (NASDAQ: ADBE) to $334.00 (from $330.00) while maintaining a Buy rating.
... MoreSarepta Therapeutics (SRPT) PT Raised to $190 at Credit Suisse
December 13, 2019 7:44 AM ESTCredit Suisse analyst Martin Auster raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $190.00 (from $185.00) while maintaining an Outperform rating after the FDA approved Vyondys 53.
The company plans to price the drug at parity with Exondys 51 or >$600,000 for a... MoreSarepta Therapeutics (SRPT) PT Raised to $215 at RBC Capital; 'Vynodys Approval A Big Win'
December 13, 2019 6:19 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $215.00 (from $200.00) while maintaining an Outperform rating following approval of Vyondys 53/golodirsen.
The analyst commented, "We view tonight's approval of Vyondys 53/golodirsen as a significant win for SRPT,... More
